GH - NASDAQ

Guardant Health, Inc.

GH·NASDAQ

$127.03

-2.4%

HealthcareMedical - Diagnostics & Research

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$16.84B

EPS-3.3200

P/E Ratio-38.26

Earnings Date07/29/2026

2.01B

Assets

36%

3Y+25.0%

5Y-11.0%

10Y+1627.0%

2.11B

Total Liabilities

30%

3Y+36.0%

5Y+131.0%

10Y+5631.0%

-99.31M

Total Equity

-29%

3Y-265.0%

5Y-107.0%

10Y-225.0%

Guardant Health, Inc. Funding & Solvency Profile

GH · NASDAQ

Current Assets

Cash & Cash Equivalents378.20M

Net Receivables137.85M

Inventory85.88M

Other Current Assets40.72M

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment304.76M

Goodwill & Intangible Assets103.18M

Long-Term Investments0.00

Other Non-Current Assets139.67M

Total Non-Current Assets444 M

Total Assets

2.01B

Financial Health Analysis

Current Ratio

4.84x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

1 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

73% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Guardant Health, Inc. Balance Sheet

GH • NASDAQ

Guardant Health, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	378.2M	525.5M	1.1B	141.6M	492.2M	833M	143.2M	140.5M	72.3M	33.6M
Short-Term Investments	823.4M	314.4M	35.1M	869.6M	440.5M	961.9M	379.6M	278.4M	149M	61.7M
Cash & Short-Term Investments	1.2B	840M	1.2B	1B	932.7M	1.8B	522.8M	419M	221.3M	95.3M
Net Receivables	137.8M	110.3M	88.8M	97.3M	97.7M	53.3M	48M	35.7M	12.8M	3.5M
Accounts Receivables	137.8M	106.9M	83.9M	97.3M	97.7M	53.3M	48M	35.7M	12.8M	3.5M
Other Receivables	0.0	3.4M	4.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	85.9M	71.1M	61.9M	51.6M	30.7M	22.7M	15.2M	9.1M	7.3M	2.8M
Prepaids	0.0	0.0	0.0	0.0	53.1M	17.5M	11.4M	5.2M	1.5M	1.6M
Other Current Assets	40.7M	33.8M	27.7M	31.5M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	1.5B	1.1B	1.3B	1.2B	1.1B	1.9B	597.4M	469M	242.9M	103.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	304.8M	279.1M	302.7M	341.9M	313.9M	100.1M	72.8M	31M	16M	12.6M
Goodwill	77.3M	3.3M	3.3M	3.3M	3.3M	3.3M	3.3M	0.0	0.0	0.0
Intangible Assets	25.9M	6.8M	9M	11.7M	14.2M	16.2M	15.4M	7.8M	8.7M	0.0
Goodwill & Intangible Assets	103.2M	10.1M	12.3M	15M	17.5M	19.4M	18.7M	7.8M	8.7M	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	698M	246.6M	268.8M	77.6M	73.3M	0.0
Other Non-Current Assets	139.7M	141.4M	124.3M	61.5M	60.9M	17.3M	4.9M	2M	2M	840K
Total Non-Current Assets	547.6M	430.5M	439.3M	418.4M	1.1B	383.4M	365.2M	118.4M	100M	13.5M
Total Assets	2B	1.5B	1.8B	1.6B	2.2B	2.3B	962.5M	587.4M	342.9M	116.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	54.4M	38.6M	51.7M	68.9M	38.5M	12M	19.2M	12.1M	5.9M	3.5M
Accounts Payable	54.4M	38.6M	51.7M	68.9M	38.5M	7.3M	16.2M	10.6M	5M	3.2M
Other Payables	0.0	0.0	0.0	0.0	0.0	4.6M	3.1M	1.5M	905K	345K
Accrued Expenses	0.0	83.2M	35.5M	29.2M	11.5M	11.4M	15.5M	5.7M	5.5M	1.4M
Short Term Debt	0.0	29.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	28M	21.9M	12.9M	6.6M	7.1M	0.0	199K	131K
Tax Payables	0.0	0.0	0.0	0.0	4.2M	4.6M	3.1M	1.5M	905K	345K
Deferred Revenue	50.8M	35.5M	18M	17.4M	11.3M	8.6M	12.3M	16.1M	3.1M	1.9M
Other Current Liabilities	197.5M	39.1M	72.7M	55.8M	120.5M	28.3M	18.6M	13M	4.9M	7.3M
Total Current Liabilities	302.7M	225.6M	205.9M	193.2M	194.7M	66.8M	72.7M	46.9M	19.6M	14.3M
NON-CURRENT LIABILITIES
Long Term Debt	1.7B	1.1B	1.1B	1.1B	1.1B	806.3M	0.0	0.0	0.0	16.5M
Other Non-Current Liabilities	127.8M	92.8M	96M	9.2M	3.9M	1.5M	8.6M	15.5M	14.2M	5.7M
Total Non-Current Liabilities	1.8B	1.4B	1.4B	1.4B	1.4B	849.4M	41.8M	15.5M	14.7M	22.6M
Capital Lease Obligations	0.0	164.3M	213.8M	231.9M	238.9M	48.2M	33.3M	216K	659K	557K
Total Liabilities	2.1B	1.6B	1.6B	1.5B	1.6B	916.2M	114.5M	62.5M	34.3M	36.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	500M	180M
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	0.0	0.0
Additional Paid-In Capital	0.0	2.4B	2.3B	1.7B	1.7B	1.9B	1.2B	764M	4.9M	7.4M
Retained Earnings	-3B	-2.6B	-2.1B	-1.7B	-1B	-606.6M	-352.8M	-280.8M	-195.7M	-107.6M
Accumulated Other Comprehensive Income/Loss	-4.9M	-5.2M	-3.7M	-19.5M	-4.8M	2.7M	1.1M	-83K	-532K	-86K
Other Total Stockholders' Equity	2.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	-99.3M	-139.6M	158.7M	60.2M	645M	1.3B	798.4M	483.2M	308.6M	79.7M
Total Equity	-99.3M	-139.6M	158.7M	60.2M	645M	1.4B	848M	525M	308.6M	79.7M
Minority Interest	0.0	0.0	0.0	0.0	0.0	57.1M	49.6M	41.8M	0.0	0.0
SUMMARY
Total Liabilities & Equity	2B	1.5B	1.8B	1.6B	2.2B	2.3B	962.5M	587.4M	342.9M	116.6M
Total Investments	823.4M	314.4M	35.1M	869.6M	1.1B	1.2B	648.4M	356M	222.3M	61.7M
Total Debt	1.7B	1.3B	1.4B	1.4B	1.4B	854.5M	40.4M	0.0	659K	17M
Net Debt	1.3B	810.5M	220.2M	1.2B	881.5M	21.5M	-102.8M	-140.5M	-71.6M	-16.6M
Shares Outstanding	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796	124,149,796

SEC Filings

GH - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 07, 2025	November 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 29, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 29, 2025	October 29, 2025	2025	View Filing

Showing 1 to 10 of 140 filings

Related Guides

Blog Categories

Continue your GH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.